Sign in

Fatty liver disease (MASLD/MASH)

Current status: Treatable, not yet curable

A common condition in which fat builds up in the liver, often linked to carrying extra weight. Most people have no signs, and it is often found by chance during tests for something else. Losing weight, eating well and exercising can cut the fat in the liver and may repair some damage. It is more common in people with type 2 diabetes, obesity or high blood pressure, and in middle-aged and older adults.

Read more about fatty liver disease (MASLD/MASH)
Where research stands todayUpdated 18 Nov 2026

Trial-stage treatments and research studies you can joinOpen trials for referral

Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.

Filters

Country
City
Distance is calculated in your browser. Your city is not sent to us.
Type
Get notified of new trialsGermany, all cities, all phases
Your ageShows only trials that take people your age.
Phase
  1. Trial-stage treatmentPhase 3Taking people
    Tests efruxifermin in adults with cirrhosis caused by fatty liver disease

    Tests efruxifermin against a placebo in adults with cirrhosis from MASH.

    Berlin, GermanyAlso Frankfurt am Main, Homburg, Leipzig, LübeckAge 18 to 80
  2. Trial-stage treatmentPhase 3Taking people
    Tests survodutide in adults with liver scarring from fatty liver disease

    Tests survodutide, a weekly injection, in adults with MASH cirrhosis.

    Berlin, GermanyAlso Cologne, Dresden, Frankfurt Am Main, Heidelberg, Homburg, Magdeburg, Mainz, Mannheim, …Age 18+
  3. Trial-stage treatmentPhase 3Soon in Germany
    Survodutide and heart structure and function in people with obesity and fatty liver disease

    Tests survodutide against placebo on heart health in adults with overweight and fatty liver.

    Bad Homburg, GermanyAlso Erlangen, Freiburg im Breisgau, Leipzig, MainzAge 18+
  4. Trial-stage treatmentPhase 3Taking people
    Tests efruxifermin in adults with liver scarring from fatty liver disease

    Tests efruxifermin against a placebo in adults with fatty liver disease and mild liver scarring.

    Berlin, GermanyAlso Frankfurt am Main, Homburg, Leipzig, Lübeck, Mainz, WürzburgAge 18 to 80
  5. Trial-stage treatmentPhase 3Taking people
    Tests survodutide in adults with liver disease and moderate or advanced liver fibrosis

    Tests survodutide weekly injections against placebo in adults with fatty liver disease and scarring.

    Berlin, GermanyAlso Cologne, Dresden, Erlangen, Frankfurt Am Main, Heidelberg, Homburg, Leipzig, Magdeburg, …Age 18+
  6. Trial-stage treatmentPhase 3Taking people
    Tests pegozafermin against placebo in liver scarring from fatty liver disease

    Tests pegozafermin doses versus placebo in adults with MASH and liver scarring.

    Chemnitz, GermanyAlso Frankfurt Am Main, Freiburg im Breisgau, Hanover, HomburgAge 18 to 80
  7. Trial-stage treatmentPhase 3Taking people
    Tests pegozafermin in adults with liver scarring from fatty liver disease

    Tests pegozafermin against placebo in adults with compensated cirrhosis from MASH.

    Chemnitz, GermanyAlso Frankfurt Am Main, Freiburg im Breisgau, Hanover, HomburgAge 18 to 75
  8. Trial-stage treatmentPhase 3Taking people
    Tests retatrutide and tirzepatide in adults with fatty liver disease at high risk

    Tests retatrutide and tirzepatide in adults with fatty liver disease to prevent serious liver problems.

    Bad Oeynhausen, GermanyAlso Berlin, Brandenburg, Dresden, Düsseldorf, Frankfurt, Hanover, Heidelberg, Homburg, …Age 18+
  9. Trial-stage treatmentPhase 3Taking people
    Tests efimosfermin alfa injection in adults with fatty liver scarring

    Tests efimosfermin alfa injection for safety in adults with MASH liver disease.

    Berlin, GermanyAlso Hamburg, Heidelberg, Homburg, Leipzig, MainzAge 18 to 75
  10. Trial-stage treatmentPhase 3Taking people
    Tests efruxifermin in adults with fatty liver disease and scarring

    Tests efruxifermin against placebo in adults with liver inflammation and fibrosis from MASH.

    Berlin, GermanyAlso Homburg, LeipzigAge 18+
  11. Trial-stage treatmentPhase 3Taking people
    Tests efruxifermin in adults with scarred liver from fatty liver disease

    Tests efruxifermin against placebo in adults with cirrhosis from MASH liver disease.

    Berlin, GermanyAlso Hanover, Homburg, LeipzigAge 18+
  12. Research studyTaking people
    Endohepatology Assessment in Adults at High Risk of Fatty Liver Disease

    Examines whether endohepatology testing changes treatment plans in adults at high risk of MASLD.

    Münster, GermanyAge 18+
  13. Trial-stage treatmentPhase 3Soon in Germany
    Tests efimosfermin against placebo in adults with cirrhosis from MASH

    Tests efimosfermin versus placebo in adults with compensated cirrhosis from MASH.

    Hamburg, GermanyAlso Heidelberg, Homburg, Leipzig, MainzAge 18+
  14. Trial-stage treatmentPhase 3Soon in Germany
    Tests efimosfermin against placebo in adults with cirrhosis caused by MASH

    Tests efimosfermin, compared with a placebo, in adults with MASH-related cirrhosis.

    Hamburg, GermanyAlso Heidelberg, Homburg, Leipzig, MainzAge 18+
  15. Trial-stage treatmentTaking people
    Studying heart function in people with alcohol-related cirrhosis receiving a liver shunt

    Checks heart changes with scans and blood tests in adults with cirrhosis getting a shunt.

    Jena, GermanyAge 18 to 99
  16. Research studyTaking people
    Blood Tests to Detect Scarring in Fatty Liver Disease

    Collects blood samples to find markers of liver scarring in fatty liver disease.

    Mainz, GermanyAge 18 to 75
  17. Trial-stage treatmentTaking people
    Eating very little on 2 days a week for fatty liver disease

    Tests a 5:2 fasting pattern in adults with metabolic dysfunction-associated steatotic liver disease.

    Homburg, GermanyAge 18 to 75
  18. Research studySoon in Germany
    Long-term follow-up of liver disease outcomes in adults with fatty liver

    Follows adults with fatty liver disease over several years to study outcomes.

    Homburg, GermanyAge 18+
  19. Research studyTaking people
    Screening for liver disease in primary care patients across Europe

    Studies a care pathway to find people with fatty liver disease early in clinics.

    Homburg, GermanyAlso MainzAge 18 to 75
  20. Research studyTaking people
    Blood Cell and Blood Factor Study in Metabolic Diseases

    Compares blood cells and circulating factors in adults with metabolic disease and healthy adults.

    Dresden, GermanyAge 18+

Search the publications

The results open on the publications page in a new tab, so this page stays as it is.

Lists with this disease filtered

Where treatment stands

These texts do not say it can be cured, but healthy lifestyle changes can reduce fat in the liver, help repair damage or stop it getting worse.

Recent EU-listed medicines are resmetirom (first EU approval August 2025) and semaglutide (March 2026), maybe first for another disease.

Approved: 2

Officially approved for this disease in the EU, the US, Switzerland or France.

Human testing stage: 18

Being tested in people. Many treatments at this stage are never approved.

Animal testing stage: 5

Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.

Lab research stage: 1

Worked on cells in the lab in a study published in the last 12 months. Most early ideas never reach people.

Support organisations

Patient organisations and helplines in Germany, for you and your family.

Fatty liver disease (MASLD/MASH) organisations in Germany

  • Berliner Leberring e.V.

    Berlin self-help association for people with liver diseases, including fatty liver, offering counselling, discussion groups, expert talks and a doctor database.

  • Deutsche Leberhilfe e.V.

    Liver patient association: telephone advice for patients and relatives, information on liver cancer (HCC) and cholangiocarcinoma, self-help group directory.

General support in Germany

  • TelefonSeelsorge Deutschland

    Free, anonymous 24/7 crisis and emotional support line across Germany (0800 111 0 111, 0800 111 0 222, 116 123), plus chat and e-mail.

  • gesund.bund.de

    The German Federal Ministry of Health's portal providing reliable, quality-assured health information on diseases, care and prevention.

  • Stiftung Unabhängige Patientenberatung Deutschland (UPD)

    Statutory independent foundation giving free advice to patients in Germany on health and health-law questions, including patient rights.

International organisations

Patient organisation umbrella bodies

Frontlight Community

Fatty liver disease (MASLD/MASH) community in Germany

People living with fatty liver disease (MASLD/MASH) and those close to them share what they went through. Posts are not medical advice: ask your doctor about your own treatment.

Offer tissue or data

There are three ways to help research move faster.

Give tissue or bloodA biobank stores your sample so many research teams can use it.See open programmes
Share your health dataA patient registry collects your health data, without your name, for research.How to join
Take part as a healthy volunteerStudies also need people without the disease, for comparison. Family and friends can help.Volunteer

Approved treatments

2 medicines are approved for fatty liver disease (MASLD/MASH) in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.

Checked on 18 Nov 2026 in the official lists of the US (FDA), the EU (European Commission and EMA) and Switzerland (Swissmedic), which we read every day. The lists of Japan (PMDA, approvals since April 2004), France (ANSM, medicines approved in France only) and Taiwan (TFDA) were checked on 11 Nov 2026. For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. Other countries' own approvals were not checked.

“Miracle cure” fact checker

Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.

What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.

Before you pay for anything, ask three things

  1. Is there a published study in people?
  2. Can I have the full price in writing?
  3. What does my doctor say?

About fatty liver disease (MASLD/MASH)

Sources: NHS, MedlinePlus

A common condition in which fat builds up in the liver, often linked to carrying extra weight. Most people have no signs, and it is often found by chance during tests for something else. Losing weight, eating well and exercising can cut the fat in the liver and may repair some damage. It is more common in people with type 2 diabetes, obesity or high blood pressure, and in middle-aged and older adults.

What is it?

In this condition fat builds up in the liver. Its new name is MASLD (metabolic dysfunction-associated steatotic liver disease); it used to be called NAFLD. It is not caused by heavy drinking. There are four stages: fat alone (most people only have this and it does not usually cause problems); fat with inflammation (MASH, once called NASH); fibrosis (scarring); and cirrhosis, severe damage that affects how well the liver works.

It is very common: it is the most common long-term liver disease. It is more likely if you are overweight, especially around the waist, if you have type 2 diabetes, high blood pressure or high cholesterol, if you are not very active, or if you are over 50. Children can get it too. The exact cause is not known.

The first signs

Usually there are no signs, and it is often found during tests for something else.

  • feeling extremely tired;
  • feeling generally unwell;
  • discomfort or pain at the top right of the tummy, under the ribs.

How doctors find out

It is usually found after blood tests or scans done for another reason show signs of problems with your liver. Your family doctor asks about your symptoms and how much alcohol you drink, and measures your height, weight and waist. More blood tests and sometimes an ultrasound scan of your tummy can show the fat, rule out other causes and check for liver damage. If there is damage to your liver, you will need to see a liver specialist in hospital. Sometimes a biopsy is done to confirm the diagnosis and check for liver damage.

Current treatment

Lifestyle changes for everyone (healthy diet, at least 150 minutes of exercise a week, weight loss, little alcohol, no smoking), with pioglitazone or vitamin E from a specialist if there is scarring.

Will it get worse?

Most people only ever have the first stage, which usually causes no problems. A small number go on to inflammation and scarring, and some to cirrhosis, which can lead to bleeding inside the body, liver failure or liver cancer. It is also linked to heart disease, kidney disease, high blood pressure and type 2 diabetes. Healthy changes lower all these risks.

Medicines: what helps, and what to watch for

If there is scarring, a liver specialist may prescribe pioglitazone or vitamin E. For people with obesity, specialists may suggest weight-loss medicines. More research is needed to know which medicines are safe and work well.

Healthy changes help most

  • exercise for at least 150 minutes a week;
  • lose weight if you are overweight: it can reduce the fat, inflammation and scarring;

Weight-loss surgery or a transplant, for some people

For people with obesity, a specialist may recommend weight-loss surgery. In very severe cases, when the liver fails, a liver transplant may be needed.

Can it get better?

Healthy changes can reduce the fat in the liver and may repair damage or stop it getting worse. More studies are needed to see whether certain medicines are safe and work well to treat MASLD; studies are listed on ClinicalTrials.gov.

See the 426 trials you can join